METXF
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, whic… Read more
Market Cap & Net Worth: METXF (METXF)
METXF (PINK:METXF) has a market capitalization of $88.57 Million ($88.57 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #21279 globally and #7635 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying METXF's stock price $2.95 by its total outstanding shares 30049494 (30.05 Million).
METXF Market Cap History: 2024 to 2025
METXF's market capitalization history from 2024 to 2025. Data shows growth from $88.57 Million to $88.57 Million (0.00% CAGR).
METXF Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how METXF's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of METXF by Market Capitalization
Companies near METXF in the global market cap rankings as of March 19, 2026.
Key companies related to METXF by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
METXF Historical Marketcap From 2024 to 2025
Between 2024 and today, METXF's market cap moved from $88.57 Million to $ 88.57 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $88.57 Million | 0.00% |
| 2024 | $88.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of METXF was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $88.57 Million USD |
| MoneyControl | $88.57 Million USD |
| MarketWatch | $88.57 Million USD |
| marketcap.company | $88.57 Million USD |
| Reuters | $88.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.